Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn


23 quality Aussie stocks for your COVID-19 watchlist

Emma Rapaport  |  20 Apr 2020Text size  Decrease  Increase  |  
Email to Friend

The Australian market can't seem to make up its mind amid the coronavirus outbreak. In March, we were in a bear market, down 21 per cent, but now we're re-entering a bull market, as shares rebound from heavy falls.

Morningstar analysts believe the aggressive social distancing measures will lead to containment of the virus in the coming months. Additional waves of the virus and social distancing measures are expected in the second half of the year, but not at current levels given the future availability of treatments.

Analysts are now forecasting a 2.9 per cent contraction in US GDP in 2020, but anticipate that the scope of the shutdown to disrupt the economy in the long term is likely overrated. They also expect a wave of drug treatments for COVID-19: Gilead Sciences’ remdesivir in the summer, targeted antibodies by the end of the year, and ultimately a vaccine in 2021.

S&P/ASX 200 | Year-to-date


Source: Morningstar Direct

Amid the uncertainty, Morningstar analysts have highlighted over 100 names they think are trading below their intrinsic value. Today, we're sorting through this list to highlight quality companies that have carved out solid (and in some cases growing) competitive advantages that will allow them to thrive for years to come.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

To find stocks to fit the bill, we screened for the following:

Economic moat: First, they need to boast wide Morningstar Economic Moat Ratings—and their Morningstar Moat Trend Ratings must be stable or positive. In other words, these companies have competitive positions that are steady or even improving.

Fair value certainty: Second, we need to have a high degree of certainty in our fair value estimates for the stocks of these companies, limiting our search to stocks with fair value uncertainties of low. This rating represents the predictability of a company's future cash flows.

Discounted: Third, the stocks of these companies must be trading at a decent discount to our fair value estimates—selling at Morningstar Ratings of 4 or 5 stars.

Top notch steward: Lastly, we tossed out companies with Poor stewardship ratings, preferring to ride along with management teams that have a proven record of being good stewards of investor capital.

Don't think of this as a list of "buys," though. Instead, think of it as a collection of names to investigate further. See the individual stock pages for full analysis.

"A 5-star rating does not suggest that the stocks won't drop further," says Morningstar director of equity research Johannes Faul. "Our aim is not to pick the bottom, but to highlight to investors that they can pick names up at a discount."

Eight stocks dropped

Since we delivered you this list last month, eight names have been dropped. Brambles (ASX: BXB), ARB Corp (ASX: ARB), Atlas Arteria (ASX: ALX), BWP Trust (ASX: BWP) and Ramsay Health Care (ASX: RHC) were all removed because their shares are now trading within a range analysts consider fairly valued.

Ramsay Health Care has seen the biggest recovery, up almost 30 per cent since the end of March.

Scentre Group (ASX: SCG), Vicinity Centres (ASX: VCX) and Sonic Healthcare (ASX: SHL) were all removed after analysts raised their fair value uncertainties to high or very high. Scentre Group and Vicinity Centres both still screen as undervalued.

"While Scentre Group faces tough times, it looks undervalued to us, as we expect eventual recovery to conditions not dissimilar to before the outbreak," Faul said.

"A threat is a forced capital raising; however, that is not our base case. The outcome depends on unknown duration of shutdowns, and government response, and thus our Uncertainty Rating moves to very high, from medium."

This is a snapshot of how these stocks stand at the time of writing: 20 April 2020. Given the current market volatility, the valuations could jump around. 

Morningstar Premium subscribers can access the full list of 100+ undervalued Australian stocks here. The latest Australian and New Zealand Best Stock Ideas list can be found here, which includes an assessment of each undervalued stock's balance sheet risk.

Wide moat stocks



Narrow moat stocks


Source: Morningstar Direct


is the editorial manager for Morningstar Australia. Connect with Emma on Twitter @rap_reports. You can email Morningstar's editorial team editorialAU[at]morningstar[dot]com

© 2022 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend